After search, choose a molecule or a kind of categories listed in the left to narrow down your filter. If you have any problems, please contact us!
Text Size:AAA

SerpinG1 / C1 inhibitor / C1IN Antibody, Rabbit PAb, Antigen Affinity Purified

DatasheetReviewsRelated ProductsProtocols
Human SerpinG1 Antibody Product Information
Immunogen:Recombinant Human SerpinG1 protein (Catalog#10995-H08H)
Clone ID:
Ig Type:Rabbit IgG
Formulation:0.2 μm filtered solution in PBS with 5% trehalose
Preparation:Produced in rabbits immunized with purified, recombinant Human SerpinG1 (rh SerpinG1; Catalog#10995-H08H; NP_000053.2; Met 1-Ala 500). SerpinG1 specific IgG was purified by human SerpinG1 affinity chromatography.
Human SerpinG1 Antibody Usage Guide
Specificity:Human Serpin G1 / C1IN
Application:WB, ELISA, IHC-P

WB: 2-10 μg/mL

ELISA: 0.5-1.0 μg/mL

This antibody can be used at 0.5-1.0 μg/mL with the appropriate secondary reagents to detect Human SerpinG1. The detection limit for Human SerpinG1 is 0.00245 ng/well .

IHC-P: 0.1-2 μg/mL

Storage:This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Human SerpinG1 Antibody WB Application Image
Human SerpinG1 Antibody IHC Application Image
SerpinG1 / C1 inhibitor / C1IN Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry
[Click to enlarge image]
Immunochemical staining of human serpinG1 in human lung with rabbit polyclonal antibody (1 µg/mL, formalin-fixed paraffin embedded sections).
Other SerpinG1 Antibody Products
C1 inhibitor/SerpinG1 Background

Plasma protease C1 inhibitor, also known as C1-inhibiting factor, C1-INH, C1 esterase inhibitor, SERPING1 and C1IN, is a serine proteinase inhibitor (serpin) that regulates activation of both the complement and contact systems. By its C-terminal part (serpin domain), characterized by three beta-sheets and an exposed mobile reactive loop, C1-INH binds, and blocks the activity of its target proteases. The N-terminal end (nonserpin domain) confers to C1-INH the capacity to bind lipopolysaccharides and E-selectin. Owing to this moiety, C1-INH intervenes in regulation of the inflammatory reaction. The heterozygous deficiency of C1-INH results in hereditary angioedema (HAE). Owing to its ability to modulate the contact and complement systems and the convincing safety profile, plasma-derived C1 inhibitor is an attractive therapeutic protein to treat inflammatory diseases other than HAE. Deficiency of C1 inhibitor results in hereditary angioedema, which is characterized by recurrent episodes of localized angioedema of the skin, gastrointestinal mucosa or upper respiratory mucosa. C1 inhibitor may prove useful in a variety of other diseases including septic shock, reperfusion injury, hyperacute transplant rejection, traumatic and hemorrhagic shock, and the increased vascular permeability associated with thermal injury, interleukin-2 therapy and cardiopulmonary bypass.

Human C1 inhibitor/SerpinG1 References
  • Davis AE 3rd. et al. (2004) Biological effects of C1 inhibitor. Drug News Perspect. 17(7): 439-46.
  • Cicardi M, et al. (2005) C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol. 27(3): 286-98.
  • Wouters D, et al. (2008) C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther. 8(8): 1225-40.
  • Cugno M, et al. (2009) C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 15(2): 69-78.
  • Product nameProduct name
    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.